VivoSeq
Oncology

Locally Advanced Lung Non-Small Cell Carcinoma

13

Pipeline Programs↗

4

Active Trials↗

8

Companies Involved↗

Locally Advanced Lung Non-Small Cell Carcinoma is an emerging landscape with 13 programs across 8 companies. The most active players are Takeda, Avyxa, McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.. 8 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

41/100

Pipeline Velocity

6/100

Mech. Concentration

13/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Takeda logo

Takeda

1 program

Phase 1A

Avyxa

2 programs

Phase 3M

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

1 program

Phase 3Bristol-Myers Squibb logo

Bristol-Myers Squibb

1 program

Phase 3Teva logo

Teva

1 program

Phase 3G

Gynecologic Oncology Group

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

77%

Small molecule

10 of 13 classified programs — the dominant modality here.

23%ALL OTHERSMonoclonal antibody215%Antibody–drug conjugate18%

Small molecule leads; the ring shows all 13 classified programs, each share of the total. Modality classified for 100% of 13 pipeline programs.

Analysis

Trial Status

4

clinical trials

Recruiting3 · 75%
Active, not recruiting1 · 25%

Clinical Trials

Trial Activity

Phase Ib Study of Brigatinib Plus Bevacizumab in Patients With ALK-Rearranged Non-Small Cell Lung Cancer (NSCLC) Who Have Previously Progressed on Prior ALK-Directed Therapy
Active, not recruiting·CCity of Hope Medical Center·Phase 1·NCT04227028·5 enrolled
A Phase I Trial Targeting Mitochondrial Metabolism With Papaverine in Combination With Chemoradiation for Stage II-III Non-Small Cell Lung Cancer
Recruiting·OOhio State University Comprehensive Cancer Center·Phase 1·NCT05136846·28 enrolled
Phase III Prospective Randomized Trial of Primary Lung Tumor Stereotactic Body Radiation Therapy Followed by Concurrent Mediastinal Chemoradiation for Locally-Advanced Non-Small Cell Lung Cancer
Recruiting·NRG Oncology·Phase 3·NCT05624996·474 enrolled
A Phase I/II Study Evaluating the Safety, Tolerability, and Efficacy of Sotorasib Plus Trastuzumab Deruxtecan in Patients With Advanced Non-Small Cell Lung Cancer With a KRASG12C Mutation
Recruiting·National Cancer Institute (NCI)·Preclinical·NCT07012031·37 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)